Detalhe da pesquisa
1.
Facilitators and barriers in the implementation and adoption of Patient Reported Outcomes Measurements in daily practice.
Value Health
; 2024 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38852667
2.
Early fecal calprotectin levels at week 8 may guide therapeutic decisions on Ustekinumab therapy in patients with Crohn's disease.
Scand J Gastroenterol
; 58(9): 980-987, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36970968
3.
Physical fitness and physical activity in fatigued and non-fatigued inflammatory bowel disease patients.
Scand J Gastroenterol
; 50(11): 1357-67, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25966749
4.
Fatigue management in patients with IBD: a randomised controlled trial.
Gut
; 63(6): 911-8, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23884638
5.
Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
Gastroenterology
; 145(5): 978-986.e5, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23954314
6.
Ustekinumab Tissue and Serum Levels in Patients With Crohn's Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction.
Inflamm Bowel Dis
; 29(7): 1038-1046, 2023 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35917118
7.
Impact of the First SARS-CoV-2 Lockdown on Adherence to Biological Treatment in Patients with Immune-Mediated Inflammatory Diseases in the Netherlands.
Patient Prefer Adherence
; 17: 167-174, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36698858
8.
Histomorphometric analysis reveals reduced bone mass and bone formation in patients with quiescent Crohn's disease.
Gastroenterology
; 140(1): 116-23, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20854819
9.
The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study.
Am J Gastroenterol
; 106(2): 319-28, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21045815
10.
Malignant transformation of perianal and enterocutaneous fistulas is rare: results of 17 years of follow-up from The Netherlands.
Scand J Gastroenterol
; 46(3): 319-25, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21299339
11.
Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease.
Eur J Gastroenterol Hepatol
; 33(1S Suppl 1): e783-e788, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34334713
12.
Vedolizumab Tissue Concentration Correlates to Mucosal Inflammation and Objective Treatment Response in Inflammatory Bowel Disease.
Inflamm Bowel Dis
; 27(11): 1813-1820, 2021 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33705545
13.
Reproductive wish represents an important factor influencing therapeutic strategy in inflammatory bowel diseases.
Scand J Gastroenterol
; 45(1): 46-50, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-19883275
14.
Impact of double-balloon enteroscopy findings on the management of Crohn's disease.
Scand J Gastroenterol
; 45(4): 483-9, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20059403
15.
Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease.
Therap Adv Gastroenterol
; 13: 1756284820979765, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33488771
16.
Individualised surveillance strategies for colorectal cancer in inflammatory bowel disease.
Gut
; 60(5): 739, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21149863
17.
Lipid phosphatase SHIP2 functions as oncogene in colorectal cancer by regulating PKB activation.
Oncotarget
; 7(45): 73525-73540, 2016 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27716613
18.
Determinants of fatigue in Crohn's disease patients.
Eur J Gastroenterol Hepatol
; 25(2): 246-51, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23111414
19.
Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation.
Inflamm Bowel Dis
; 18(9): 1634-40, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22069022